drugset / Trial / NCT01787539
The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer
Phase 2/3
Unknown
180 enrolled
Medical University of Lublin
St Johns' Oncology Center in Lublin · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Taking into account the substantial doubts concerning the potential benefit of postoperative part in the perioperative chemotherapy regimen we designed a study assessing value of this approach in gastric cancer. To improve compliance with a protocol regimen of this aggressive combined therapy we replaced tested in the MAGIC trial ECF regimen with more effective and better tolerable EOX chemotherapy regimen. The value of postoperative three-cycle EOX regimen will be tested in patients with locoregionally advanced gastric cancer with positive pathological response to preoperative three-cycle EOX chemotherapy regimen. The patients will be randomized to the postoperative chemotherapy or to the follow-up arm.
Timeline
- Start
- 2013-02
- Primary completion
- 2017-02
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Subject | Epirubicin | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |